Arrien Pharmaceuticals LLC

12 patents currently held · Updated Nov 15, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Mar 2032

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due May 17, 2027
The maintenance fee for Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors (US 9,187,473) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
1 fee due Jun 8, 2027
The maintenance fee for SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS ITK AND JAK INHIBITORS (US 9,206,188) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
1 fee due Aug 16, 2027
The maintenance fee for Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (US 9,260,426) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,791,112	Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors In force Term ends Mar 30, 2032 · From the USPTO record	In force	Term ends Mar 30, 2032	From the USPTO record
US 9,187,473	Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors In force Term ends Mar 30, 2032 · From the USPTO record	In force	Term ends Mar 30, 2032	From the USPTO record
US 9,669,028	Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors In force Term ends Mar 30, 2032 · From the USPTO record	In force	Term ends Mar 30, 2032	From the USPTO record
US 9,962,382	Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors In force Term ends Jun 14, 2032 · From the USPTO record	In force	Term ends Jun 14, 2032	From the USPTO record
US 9,260,426	Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors In force Term ends Dec 9, 2033 · From the USPTO record	In force	Term ends Dec 9, 2033	From the USPTO record
US 9,951,062	Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors In force Ends no later than Dec 9, 2033 · From the USPTO record	In force	Ends no later than Dec 9, 2033	From the USPTO record
US 9,206,188	SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS ITK AND JAK INHIBITORS In force Term ends Apr 16, 2034 · High confidence	In force	Term ends Apr 16, 2034	High confidence
US 9,834,551	Substituted Pyrrolo[2,3-b]pyrazines and Substituted Pyrazolo[3,4-b]pyridines as Itk and Jak Kinase Inhibitors In force Term ends Jun 28, 2034 · High confidence	In force	Term ends Jun 28, 2034	High confidence
US 9,446,047	Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis In force Term ends Aug 27, 2034 · Medium confidence	In force	Term ends Aug 27, 2034	Medium confidence
US 10,172,866	Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis In force Ends no later than Aug 27, 2034 · Medium confidence	In force	Ends no later than Aug 27, 2034	Medium confidence

10 of 12 patents shown.

Pro members see all 12.

Pro members: see all 12 patents

Also on record, not counted in the 12: 1 patent in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

Every application published under this name has become a patent.